1. Home
  2. NMRA vs NNNN Comparison

NMRA vs NNNN Comparison

Compare NMRA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neumora Therapeutics Inc.

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$0.67

Market Cap

302.0M

Sector

N/A

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$6.18

Market Cap

340.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMRA
NNNN
Founded
2019
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
302.0M
340.2M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
NMRA
NNNN
Price
$0.67
$6.18
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $7.50
N/A
AVG Volume (30 Days)
★ 1.5M
241.6K
Earning Date
05-07-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 5.23
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$5.13
52 Week High
$3.65
$51.33

Technical Indicators

Market Signals
Indicator
NMRA
NNNN
Relative Strength Index (RSI) 22.81 40.72
Support Level N/A $5.13
Resistance Level $1.74 $12.10
Average True Range (ATR) 0.10 0.53
MACD -0.01 0.19
Stochastic Oscillator 6.63 57.69

Price Performance

Historical Comparison
NMRA
NNNN

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: